Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **Peptide-major histocompatibility complex-T cell receptor (Peptide-MHC-TCR) interface** is the structural and functional contact zone where a T cell receptor (TCR) binds to a peptide presented by a major histocompatibility complex (MHC) molecule on an antigen-presenting cell[1][4][5]. This interaction is fundamental to the cellular arm of the adaptive immune response, dictating the specificity and activation of T cells. The interface comprises three main components—the peptide (usually 8–15 amino acids long), the MHC molecule (often highly polymorphic), and the TCR itself (formed by variable α/β chains)[5]. Structural studies show that the TCR typically recognizes the antigenic peptide by using its hypervariable complementarity-determining region 3 (CDR3) loops, while the CDR1 and CDR2 loops primarily interact with the MHC molecule[1][4]. The docking geometry and conformational changes at the interface are critical for antigen specificity and avoidance of off-target or autoimmune responses[1][3][4][5]. Extensive structural variability and flexibility at this site allow recognition of diverse peptide antigens, but also pose challenges for predicting specificity and engineering safe therapeutics[1][2][6]. The Peptide-MHC-TCR interface is an active target in immunotherapy, including TCR-engineered cell therapies, peptide-MHC vaccines, and structural-based drug design aiming to manipulate immune recognition or tolerance[4][5][6]. Safety concerns largely stem from the potential to trigger undesirable immune reactions due to cross-reactivity or loss of TCR specificity, underscoring the need for robust structure-guided approaches in clinical applications[4][6].
Modulation of antigen recognition specificity; Induction of T cell activation and cytotoxicity; Allosteric modulation of TCR-pMHC binding; Enhanced immune synapse formation
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peptide-major histocompatibility complex-T cell receptor interface.